BioPharmSignal logoBioPharmSignal

Biotech News

Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

Corvus Pharmaceuticals (CRVS)Corvus PharmaceuticalsClinical readout

Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biology SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.

Related news

CRVSCorvus Pharmaceuticals2026-08-27 11:30 EST

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

RVMDRevolution Medicines2026-09-02 21:50 EST

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

REGNRegeneron Pharmaceuticals2026-10-01 15:30 EST

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

CRVSCorvus Pharmaceuticals2026-09-03 12:30 EST

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

FATEFate Therapeutics2026-09-25 11:00 EST

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

View all latest news

Corvus Pharmaceuticals

ITK Inhibition Corvus Pharmaceuticals develops therapies based on inhibition of interleukin-2-inducible T-cell kinase, or ITK. The approach is intended to rebalance immune-cell activity in inflammatory diseases and cancer. Soquelitinib Soquelitinib is an oral, selective ITK inhibitor. Its lead immunology program is a Phase 2 study in...

Recent company news

CRVSCorvus Pharmaceuticals2026-09-30 20:05 EST

Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

CRVSCorvus Pharmaceuticals2026-09-03 12:30 EST

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

CRVSCorvus Pharmaceuticals2026-08-27 11:30 EST

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

CRVSCorvus Pharmaceuticals2026-08-06 20:01 EST

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

CRVSCorvus Pharmaceuticals2026-07-30 20:01 EST

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

Stock data

Close
10.56 USD
Market cap
983.02M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States